Analyzing CG Oncology (NASDAQ:CGON) and iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Earnings & Valuation

This table compares iTeos Therapeutics and CG Oncology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	$35.00 million	9.13	-$112.64 million	($3.04)	-2.75
CG Oncology	$662,000.00	3,058.21	-$48.61 million	($1.51)	-17.59

CG Oncology has lower revenue, but higher earnings than iTeos Therapeutics. CG Oncology is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

iTeos Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, CG Oncology has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares iTeos Therapeutics and CG Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	-20.11%	-17.50%
CG Oncology	-10,642.98%	-18.97%	-15.36%

Analyst Recommendations

This is a summary of current ratings and recommmendations for iTeos Therapeutics and CG Oncology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	4	3	0	2.43
CG Oncology	0	1	9	1	3.00

iTeos Therapeutics presently has a consensus price target of $17.86, suggesting a potential upside of 113.86%. CG Oncology has a consensus price target of $58.22, suggesting a potential upside of 119.21%. Given CG Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe CG Oncology is more favorable than iTeos Therapeutics.

Institutional and Insider Ownership

97.2% of iTeos Therapeutics shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 12.5% of iTeos Therapeutics shares are held by company insiders. Comparatively, 7.4% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

CG Oncology beats iTeos Therapeutics on 9 of the 15 factors compared between the two stocks.

About iTeos Therapeutics

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.